Compare Biocon with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SANOFI INDIA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SANOFI INDIA BIOCON /
SANOFI INDIA
 
P/E (TTM) x 30.6 42.9 71.3% View Chart
P/BV x 3.9 8.7 44.4% View Chart
Dividend Yield % 0.3 1.0 25.4%  

Financials

 BIOCON    SANOFI INDIA
EQUITY SHARE DATA
    BIOCON
Mar-19
SANOFI INDIA
Dec-18
BIOCON /
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7076,840 10.3%   
Low Rs5544,630 12.0%   
Sales per share (Unadj.) Rs91.91,203.1 7.6%  
Earnings per share (Unadj.) Rs16.7165.3 10.1%  
Cash flow per share (Unadj.) Rs24.2209.9 11.5%  
Dividends per share (Unadj.) Rs1.0084.00 1.2%  
Dividend yield (eoy) %0.21.5 10.8%  
Book value per share (Unadj.) Rs101.6963.6 10.5%  
Shares outstanding (eoy) m600.0023.03 2,605.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.8 143.9%   
Avg P/E ratio x37.734.7 108.7%  
P/CF ratio (eoy) x26.127.3 95.4%  
Price / Book Value ratio x6.26.0 104.2%  
Dividend payout %6.050.8 11.8%   
Avg Mkt Cap Rs m378,330132,078 286.4%   
No. of employees `0006.13.3 185.7%   
Total wages/salary Rs m11,6534,068 286.5%   
Avg. sales/employee Rs Th8,994.38,393.8 107.2%   
Avg. wages/employee Rs Th1,900.71,232.4 154.2%   
Avg. net profit/employee Rs Th1,635.31,153.0 141.8%   
INCOME DATA
Net Sales Rs m55,14427,708 199.0%  
Other income Rs m1,444897 161.0%   
Total revenues Rs m56,58828,605 197.8%   
Gross profit Rs m15,8836,235 254.7%  
Depreciation Rs m4,4781,027 436.0%   
Interest Rs m7097 10,128.6%   
Profit before tax Rs m12,1406,098 199.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1232,292 92.6%   
Profit after tax Rs m10,0263,806 263.4%  
Gross profit margin %28.822.5 128.0%  
Effective tax rate %17.537.6 46.5%   
Net profit margin %18.213.7 132.4%  
BALANCE SHEET DATA
Current assets Rs m48,22815,922 302.9%   
Current liabilities Rs m30,3766,235 487.2%   
Net working cap to sales %32.435.0 92.6%  
Current ratio x1.62.6 62.2%  
Inventory Days Days6864 107.3%  
Debtors Days Days8621 409.8%  
Net fixed assets Rs m64,1307,539 850.6%   
Share capital Rs m3,000230 1,304.3%   
"Free" reserves Rs m57,98021,962 264.0%   
Net worth Rs m60,98022,192 274.8%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92429,839 408.6%  
Interest coverage x18.1872.1 2.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.9 48.7%   
Return on assets %8.812.8 68.9%  
Return on equity %16.417.2 95.9%  
Return on capital %16.827.5 60.9%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,5067,587 204.4%   
Fx outflow Rs m10,3997,145 145.5%   
Net fx Rs m5,107442 1,155.4%   
CASH FLOW
From Operations Rs m11,5463,739 308.8%  
From Investments Rs m-7,138-731 976.5%  
From Financial Activity Rs m-2,417-1,972 122.6%  
Net Cashflow Rs m2,1031,036 203.0%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  STERLING BIOTECH  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 22, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS